Open AccessEfficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
Author(s) -
Geng Qian,
Xuan Li,
Qingjiao Sun,
Zhengzhong Wang
Publication year - 2022
Publication title -
cardiology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.573
H-Index - 33
eISSN - 1897-5593
pISSN - 1898-018X
DOI - 10.5603/cj.a2021.0110
Subject(s) - alirocumab , medicine , evolocumab , pcsk9 , tolerability , placebo , randomized controlled trial , odds ratio , gastroenterology , cardiology , cholesterol , apolipoprotein b , adverse effect , lipoprotein , ldl receptor , pathology , alternative medicine , apolipoprotein a1
Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab in patients with atherosclerotic cardiovascular disease (ASCVD).